Study guide

20.3 Pediatric Public Health Disparities & Special Population Advocacy

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

20.3 Pediatric Public Health Disparities & Special Population Advocacy

Key Takeaways Explain This Topic AI

The CDC blood lead reference value is 3.5 mcg/dL; oral succimer (DMSA) chelation is indicated for blood lead levels of 45 to 69 mcg/dL (10 mg/kg TID for 5 days, then BID for 14 days), whereas blood lead levels >=70 mcg/dL or encephalopathy mandate emergency dual chelation with parenteral BAL (75 mg/m2 IM q4h) initiating at least 4 hours before IV calcium disodium EDTA.

Disodium EDTA (Na2EDTA) is strictly contraindicated and carries an FDA Black Box Warning for fatal hypocalcemic cardiac arrest; only calcium disodium EDTA (CaNa2EDTA) may be utilized for lead chelation.

In technology-dependent children with enteral access, high-sorbitol liquid formulations (>1-2 g sorbitol/day) trigger severe osmotic diarrhea, while administering medications via jejunal tubes bypasses gastric acidity and first-pass hepatic metabolism, requiring formulation adjustments and 5 to 10 mL water flushes between drugs.

In pediatric chemical nerve agent exposures, atropine is dosed at 0.02 to 0.05 mg/kg IV/IM (minimum 0.1 mg to prevent paradoxical bradycardia, titrated to pulmonary drying) co-administered with pralidoxime 20 to 50 mg/kg IV; radiation emergencies dictate immediate weight/age-stratified potassium iodide (16.25 mg neonates, 32.5 mg infants 1 mo–3 yr, 65 mg children 3–18 yr <=68 kg, 130 mg >68 kg).

The Best Pharmaceuticals for Children Act (BPCA) provides a 6-month patent exclusivity extension for voluntary pediatric studies, while the Pediatric Research Equity Act (PREA) mandates pediatric assessment plans for new drug applications, advancing drug labeling for pediatric orphan diseases.

Last updated: September 2026

20.3 Pediatric Public Health Disparities & Special Population Advocacy

Pediatric health outcomes are profoundly shaped by structural inequities, environmental exposures, and healthcare delivery barriers. The Board-Certified Pediatric Pharmacy Specialist (BCPPS) must extend clinical expertise beyond bedside pharmacokinetics into public health advocacy, addressing Social Determinants of Health (SDOH), optimizing care for technology-dependent children, championing pediatric orphan drug access, and leading disaster preparedness initiatives.

Social Determinants of Health (SDOH) & Pediatric Chronic Illness

Healthy People 2030 categorizes SDOH into five interrelated domains that drive systemic pediatric health disparities: The Five SDOH Domains in Pediatric Pharmacotherapy:

  • ┌───────────────────────────────────────────────┬───────────────────────────────────────────────┐
  • │ SDOH Domain (Healthy People 2030) │ Direct Pediatric Clinical & Pharmacotherapeutic Impact│
  • ├───────────────────────────────────────────────┼───────────────────────────────────────────────┤
  • │ 1. Economic Stability │ Inability to afford co-pays for controller │
  • │ (Poverty, employment, food insecurity) │ medications (ICS, insulin); medication rationing.│
  • │ 2. Neighborhood & Built Environment │ Substandard housing: indoor mold, cockroach/ │
  • │ (Lead paint, air pollution, green space) │ rodent allergens trigger severe asthma; lead. │
  • │ 3. Education Access & Quality │ Low caregiver health literacy; liquid dosing │
  • │ (Literacy, school health services) │ errors; lack of full-time school nurses. │
  • │ 4. Food Insecurity & Nutrition │ Food deserts drive cheap carbohydrate intake, │
  • │ (Hunger, lack of fresh foods) │ destabilizing glycemic control in T1D and T2D.│
  • │ 5. Healthcare Access & Quality │ Insurance churn (Medicaid lapses); lack of │
  • │ (Medicaid coverage, pharmacy deserts) │ pediatric specialists and specialty pharmacies│
  • └───────────────────────────────────────────────┴───────────────────────────────────────────────┘
  • Clinical Impact on Urban Pediatric Asthma & Diabetes

Urban Pediatric Asthma: Children residing in low-income urban neighborhoods experience up to four-fold higher hospitalization rates for acute asthma exacerbations. Substandard multi-family housing exposes infants to indoor pest allergens ( Blattella germanica [cockroach allergen Bla g 1 and Bla g 2] and Mus musculus [mouse urinary protein Mus m 1]) and outdoor particulate matter (PM2.5, nitrogen dioxide). Financial strain causes families to underfill daily inhaled corticosteroid (ICS) maintenance prescriptions, relying instead on overused short-acting beta-agonists (SABA) during acute respiratory failure.

Pediatric Diabetes Disparities: Families experiencing food insecurity face cyclic feast-or-famine nutritional patterns that trigger severe nocturnal hypoglycemia followed by rebound diabetic ketoacidosis (DKA). Furthermore, stark racial and socioeconomic disparities exist in the prescribing and insurance authorization of Continuous Glucose Monitors (CGMs) and Automated Insulin Delivery (AID) smart pumps , with Medicaid-insured children receiving technology at less than half the rate of commercially insured peers.

Environmental Lead Exposure: Screening, Toxicology & Chelation

Lead ( P b 2 + Pb^{2+} P b 2 + ) is a potent, non-threshold neurotoxin that displaces divalent cations ( C a 2 + Ca^{2+} C a 2 + , Z n 2 + Zn^{2+} Z n 2 + , F e 2 + Fe^{2+} F e 2 + ). Lead inhibits delta-aminolevulinic acid dehydratase (ALAD) and ferrochelatase , causing microcytic sideroblastic anemia. In the central nervous system, lead disrupts synaptic pruning, neurotransmitter release, and blood-brain barrier integrity, producing irreversible loss of cognitive IQ, attention-deficit/hyperactivity disorder (ADHD), and behavioral executive dysfunction. Lead Chelation Decision Algorithm Based on Venous Blood Lead Level (BLL):

  • [Venous BLL Drawn]
  • │
  • ┌────────────────────────────┼────────────────────────────┐
  • ▼ ▼ ▼
  • [BLL < 45 mcg/dL] [BLL 45 to 69 mcg/dL] [BLL >= 70 mcg/dL or
  • Chelation NOT indicated • Chelation INDICATED Encephalopathy Present]
  • Identify & abate source • Oral Succimer (DMSA): • MEDICAL EMERGENCY
  • Nutritional intake: 10 mg/kg TID x 5 days, • Inpatient PICU admission

Optimize Fe, Ca, Vit C then 10 mg/kg BID x 14 days • Dual Chelation Therapy:

  • Serial BLL monitoring • Check rebound BLL at 1. BAL: 75 mg/m2 IM q4h
  • 7 to 14 days post-tx 2. CaNa2EDTA: 1,000-1,500
  • Alternative: IV CaNa2EDTA mg/m2/day continuous IV
  • 1,000 mg/m2/day x 5 days • BAL MUST precede EDTA

by >= 4 HOURS!

Clinical Chelation Regimens & Critical Safety Rules

CDC Reference Value: The CDC blood lead reference value (BLRV) is 3.5 mcg/dL (established from NHANES data). No safe blood lead level in children has been identified.

BLL <45 mcg/dL: Chelation therapy is NOT recommended . Chelation does not reverse neurodevelopmental deficits at these levels and carries adverse drug risks. Management consists of environmental source inspection and abatement, correcting iron and calcium deficiencies (which upregulate divalent metal transporter-1 [DMT-1], increasing intestinal lead absorption), and frequent serial venous BLL monitoring.

BLL 45 to 69 mcg/dL (Asymptomatic or Mild Symptoms): Chelation is indicated .

First-Line Agent: Oral Succimer (DMSA [meso-2,3-dimercaptosuccinic acid]):

Dose: 10 mg/kg (or 350 mg/m2) orally every 8 hours (three times daily) for 5 days , followed by 10 mg/kg (or 350 mg/m2) orally every 12 hours (twice daily) for 14 days (total course duration: 19 days).

Administration: Capsules may be opened and sprinkled onto a small spoonful of applesauce, yogurt, or fruit puree for young children.

Post-Chelation Rebound: Blood lead levels rebound significantly 7 to 14 days after completing therapy as lead stored in trabecular bone redistributes into the vascular compartment. Venous BLL must be rechecked 7 to 14 days post-treatment to determine whether a second 19-day course is required (minimum 2-week rest interval between courses).

Alternative (if vomiting or oral succimer intolerant): Parenteral Calcium Disodium EDTA (CaNa2EDTA) : 1,000 mg/m2/day administered as a continuous IV infusion over 5 days.

BLL >=70 mcg/dL or Acute Lead Encephalopathy (Emergency):

Characterized by encephalopathy (ataxia, persistent vomiting, altered mental status, stupor, convulsions, coma).

Dual Chelation Regimen:

Agent 1: Dimercaprol (BAL [British Anti-Lewisite] in Oil): 75 mg/m2 (or 4 mg/kg) deep intramuscularly every 4 hours .

Agent 2: Calcium Disodium EDTA (CaNa2EDTA): 1,000 to 1,500 mg/m2/day as a continuous IV infusion (or divided every 4 hours IV/IM).

MANDATORY SEQUENCING RULE: BAL MUST be administered at least 4 hours before initiating Calcium Disodium EDTA.

Rationale: BAL is lipophilic and rapidly crosses the blood-brain barrier to chelate intracellular CNS lead. If Calcium Disodium EDTA (a hydrophilic extracellular chelator) is administered alone or prior to BAL, it mobilizes large quantities of lead from skeletal and soft-tissue pools into the blood, acutely crossing into the brain and worsening fatal cerebral edema and herniation.

CRITICAL BLACK BOX WARNING (Disodium EDTA vs. Calcium Disodium EDTA):

Disodium EDTA ( N a 2 E D T A Na_2EDTA N a 2 ​ E D T A , Endrate) is STRICTLY CONTRAINDICATED and must NEVER be used for lead chelation. Disodium EDTA binds serum calcium, precipitating severe hypocalcemia, tetany, fatal cardiac arrhythmias, and cardiac arrest. Only Calcium Disodium EDTA ( C a N a 2 E D T A CaNa_2EDTA C a N a 2 ​ E D T A , Calcium Disodium Versenate) contains bound calcium and is safe for clinical use.

BAL Pearl: BAL is formulated in peanut oil; it is contraindicated in patients with peanut allergy and causes acute hemolysis in Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Children with Medical Complexity (CMC) & Technology Dependence

Children with Medical Complexity (CMC) represent less than 1% of the pediatric population but account for over one-third of pediatric healthcare expenditures. Technology-dependent children—those requiring enteral feeding tubes (G-tube, GJ-tube, J-tube), tracheostomies, or home mechanical ventilation—present unique pharmacotherapeutic vulnerabilities. Enteral Tube Pharmacotherapy Considerations:

  • ┌────────────────────────────┬────────────────────────────────────────────────────────┐
  • │ Clinical Factor │ Pharmacotherapeutic Risk & BCPPS Mitigation Strategy │
  • ├────────────────────────────┼────────────────────────────────────────────────────────┤
  • │ Excipient Toxicity: │ Liquid elixirs/solutions often contain 10% to 50% │
  • │ Sorbitol Accumulation │ sorbitol. Doses exceeding 1 to 2 g/day trigger severe │
  • │ │ osmotic diarrhea, cramping, and failure to thrive. │
  • │ │ ► Action: Switch to crushed immediate-release tablets. │
  • │ Physical Tube Clogging │ Administering viscous suspensions or inadequately │
  • │ │ crushed tablets occludes narrow feeding tubes. │
  • │ │ ► Action: Flush with 5–10 mL warm water before/after. │
  • │ Jejunal vs. Gastric │ Medications requiring gastric acid (ketoconazole, iron)│
  • │ Administration Bypass │ or local gastric coating (sucralfate) FAIL if given │
  • │ │ into a J-tube. J-tube delivery bypasses first-pass │
  • │ │ hepatic extraction, altering drug bioavailability. │
  • └────────────────────────────┴────────────────────────────────────────────────────────┘
  • Enteral Drug Administration Principles

Dosage Form Integrity: Extended-release (ER, XR, XL), sustained-release (SR), enteric-coated (EC), and sublingual tablets must never be crushed for tube delivery. Crushing ER formulations produces "dose dumping" and acute toxicity, while crushing enteric-coated granules destroys acid-labile molecules (e.g., omeprazole) in the stomach or causes severe gastric mucosal irritation.

The Sorbitol Diarrhea Trap: In CMC children experiencing chronic refractory diarrhea, pharmacists must audit the sorbitol content of all liquid medications. Common liquid products (e.g., acetaminophen liquid, valproic acid syrup, potassium chloride elixir) contain high sorbitol concentrations. Doses >1 to 2 g/day induce osmotic shifts, electrolyte wasting, and feeding intolerance.

Flushing Protocol: Flush enteral tubes with 5 to 10 mL of water (1 to 3 mL in fluid-restricted neonates) prior to medication administration, between separate medications, and following the final dose. Never mix multiple medications together prior to administration due to physical incompatibilities and precipitations.

Orphan Drug Act & Pediatric Rare Disease Legislation

Over 7,000 rare diseases affect approximately 30 million Americans; over 50% of rare diseases affect children , and 30% of affected children die before their 5th birthday. Historically, the pharmaceutical industry neglected pediatric rare disease drug development due to small market sizes and complex clinical trial logistics.

Key Legislative Frameworks

The Orphan Drug Act (ODA) of 1983:

Defines a rare disease as affecting fewer than 200,000 individuals in the United States .

Incentives: Grants sponsors 7 years of guaranteed market exclusivity upon FDA approval, 25% clinical research tax credits , exemption from FDA Prescription Drug User Fee Act (PDUFA) application fees, and specialized orphan research grants.

Best Pharmaceuticals for Children Act (BPCA) of 2002:

Provides financial incentives for voluntary pediatric drug studies.

When the FDA issues a formal Written Request (WR) asking a manufacturer to study an on-patent drug in pediatric populations, completing the studies grants the sponsor an additional 6-month pediatric patent exclusivity extension across the entire active ingredient line.

Pediatric Research Equity Act (PREA) of 2003:

Unlike voluntary BPCA, PREA gives the FDA mandatory regulatory authority to require pediatric assessments (Pediatric Study Plans [PSP]) for new drug applications involving a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration.

Expanded Access (Compassionate Use) Protocols:

Allows pediatric patients with immediately life-threatening illnesses who exhaust standard therapies to access investigational drugs outside clinical trials.

Emergency Single-Patient IND: Authorizes emergency drug shipment within 24 hours upon FDA verbal concurrence, with institutional review board (IRB) notification required within 5 working days.

Pediatric Emergency Disaster Preparedness & Countermeasures

Children are uniquely vulnerable during chemical, biological, radiologic, or toxicologic mass-casualty incidents due to specific physiological traits:

Higher minute ventilation per kilogram of body weight (accelerates inhalation of aerosolized toxins).

Larger body surface area-to-mass ratio and thinner stratum corneum (increases dermal chemical absorption and hypothermia risk).

Shorter stature (places pediatric airways closer to the ground where heavy chemical vapors [e.g., chlorine, sarin] concentrate).

Immature hepatic and renal metabolic pathways (delays toxicant elimination). Pediatric Disaster Medical Countermeasures Reference:

  • ┌────────────────────────────┬────────────────────────────────────────────────────────┐
  • │ Exposure / Toxin │ Pediatric Antidote Regimen & Critical Dosing Rules │
  • ├────────────────────────────┼────────────────────────────────────────────────────────┤
  • │ **Nerve Agents /** │ **Atropine:** 0.02 to 0.05 mg/kg IV/IM (minimum │
  • │ **Organophosphates** │ dose 0.1 mg; max initial dose 2 mg); repeat q3-5min │
  • │ (Sarin, Soman, VX) │ until bronchial secretions dry ("atropinization"). │
  • │ │ **Pralidoxime (2-PAM):** 20 to 50 mg/kg IV over │
  • │ │ 30 min (or IM), then 10–20 mg/kg/hr infusion. │
  • │ │ Auto-injectors: Pediatric AtroPen (0.25, 0.5, 1, 2 mg).│
  • ├────────────────────────────┼────────────────────────────────────────────────────────┤
  • │ **Radiologic Nuclear** │ **Potassium Iodide (KI):** Blocks thyroid I-131 uptake.│
  • │ **Emergency** │ Administer within 2 to 4 hours of exposure. │
  • │ (Nuclear reactor meltdown) │ • Neonates (0–1 mo): **16.25 mg** orally once daily. │
  • │ │ • Infants (1 mo–3 yr): **32.5 mg** orally once daily. │
  • │ │ • Children (3–18 yr <=68 kg): **65 mg** orally daily. │
  • │ │ • Adolescents (>68 kg) / Adults: **130 mg** daily. │
  • ├────────────────────────────┼────────────────────────────────────────────────────────┤
  • │ **Cyanide Poisoning** │ **Hydroxocobalamin (Cyanokit):** 70 mg/kg IV over │
  • │ (Structure fire smoke) │ 15 minutes (max single dose 5 g). Safe in smoke │
  • │ │ inhalation (avoids nitrite-induced methemoglobinemia). │
  • └────────────────────────────┴────────────────────────────────────────────────────────┘
  • Practice Pearls & BCPPS Exam Traps

Exam Trap 1: Calcium Disodium EDTA vs. Disodium EDTA: Any board exam question offering "Disodium EDTA (Na2EDTA)" for lead poisoning is an absolute safety distractor. Na2EDTA causes fatal hypocalcemic cardiac arrest. The only correct agent is Calcium Disodium EDTA ( C a N a 2 E D T A CaNa_2EDTA C a N a 2 ​ E D T A ) .

Exam Trap 2: BAL and EDTA Sequencing: Never administer Calcium Disodium EDTA before or without BAL in severe lead toxicity (BLL >=70 mcg/dL or encephalopathy). BAL must be given at least 4 hours before EDTA to prevent lead mobilization into the brain.

Exam Trap 3: Low Blood Lead Levels (<45 mcg/dL): Do not initiate chelation for BLL 20, 30, or 40 mcg/dL. The clinical threshold for chelation is BLL >=45 mcg/dL .

Exam Trap 4: Nerve Agent Atropine Minimum Dosing: When dosing atropine in infants, remember the absolute minimum dose of 0.1 mg . Administering doses <0.1 mg can produce paradoxical central vagal stimulation, worsening bradycardia.